Just a few weeks after Novartis revealed it was considering a sale of its generics business Sandoz, there are reports that a potential buyer has already come forward.
On the heels of a late-stage clinical trial failure, Vifor Pharma has moved to bolster its pipeline by acquiring Spain's Sanifit and fellow Swiss biotech Inositec for a combined value of €2
In 2018, the takeover of Athenahealth by Veritas Capital and Elliott Management for $5.5 billion was the biggest digital health transaction of the year, but it could be dwarfed by their exi
Danish drugmaker Novo Nordisk must like what it has seen in its two-year-old alliance with gene-silencing specialist Dicerna Pharma – it has just agreed to acquire the biotech for $3.3 bill
After decades of a diversified healthcare business model, Johnson & Johnson has announced it plans to split off its consumer health division from its pharma and medical device operation
Switzerland's Social Democratic Party has argued that the government should step in and acquire Novartis' generics unit Sandoz if the company decides to sell it, according to local press re